JP2019500374A5 - - Google Patents

Download PDF

Info

Publication number
JP2019500374A5
JP2019500374A5 JP2018533649A JP2018533649A JP2019500374A5 JP 2019500374 A5 JP2019500374 A5 JP 2019500374A5 JP 2018533649 A JP2018533649 A JP 2018533649A JP 2018533649 A JP2018533649 A JP 2018533649A JP 2019500374 A5 JP2019500374 A5 JP 2019500374A5
Authority
JP
Japan
Prior art keywords
optionally substituted
pharmaceutically acceptable
alkyl
solvate
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018533649A
Other languages
English (en)
Japanese (ja)
Other versions
JP6906525B2 (ja
JP2019500374A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/068431 external-priority patent/WO2017112902A1/en
Publication of JP2019500374A publication Critical patent/JP2019500374A/ja
Publication of JP2019500374A5 publication Critical patent/JP2019500374A5/ja
Priority to JP2021103372A priority Critical patent/JP2021167323A/ja
Application granted granted Critical
Publication of JP6906525B2 publication Critical patent/JP6906525B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018533649A 2015-12-23 2016-12-22 グルココルチコイド受容体の阻害剤 Expired - Fee Related JP6906525B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021103372A JP2021167323A (ja) 2015-12-23 2021-06-22 グルココルチコイド受容体の阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562387282P 2015-12-23 2015-12-23
US62/387,282 2015-12-23
PCT/US2016/068431 WO2017112902A1 (en) 2015-12-23 2016-12-22 Inhibitors of glucocorticoid receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021103372A Division JP2021167323A (ja) 2015-12-23 2021-06-22 グルココルチコイド受容体の阻害剤

Publications (3)

Publication Number Publication Date
JP2019500374A JP2019500374A (ja) 2019-01-10
JP2019500374A5 true JP2019500374A5 (cg-RX-API-DMAC10.html) 2020-01-30
JP6906525B2 JP6906525B2 (ja) 2021-07-21

Family

ID=59091239

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018533649A Expired - Fee Related JP6906525B2 (ja) 2015-12-23 2016-12-22 グルココルチコイド受容体の阻害剤
JP2021103372A Ceased JP2021167323A (ja) 2015-12-23 2021-06-22 グルココルチコイド受容体の阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021103372A Ceased JP2021167323A (ja) 2015-12-23 2021-06-22 グルココルチコイド受容体の阻害剤

Country Status (7)

Country Link
US (2) US11124537B2 (cg-RX-API-DMAC10.html)
EP (1) EP3394078A4 (cg-RX-API-DMAC10.html)
JP (2) JP6906525B2 (cg-RX-API-DMAC10.html)
CN (1) CN108699102A (cg-RX-API-DMAC10.html)
AU (2) AU2016377702B2 (cg-RX-API-DMAC10.html)
CA (1) CA3009522A1 (cg-RX-API-DMAC10.html)
WO (1) WO2017112902A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3009522A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
US11110103B2 (en) 2015-12-23 2021-09-07 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
CN108713023B (zh) 2015-12-23 2021-10-26 欧瑞克制药公司 糖皮质激素受体抑制剂
EP3523315B1 (en) * 2016-10-07 2021-03-24 Oric Pharmaceuticals, Inc. Inhibitor of glucocorticoid receptor
US11998606B2 (en) 2018-04-13 2024-06-04 Board Of Regents, The University Of Texas System Compounds and methods for selective proteolysis of glucocorticoid receptors
WO2022031642A2 (en) * 2020-08-04 2022-02-10 Oric Pharmaceuticals, Inc. Uses of glucocorticoid receptor (gr) antagonist and androgen receptor (ar) degrader combinations
EP4203936A4 (en) * 2020-08-31 2024-10-30 The Trustees of Indiana University METHODS FOR THE PREVENTION OF HIGH-GRADE SEROUS OVARIAN CARCINOMA AND BREAST CANCER BY ADMINISTRATION OF ANTIPROGESTINS
WO2023000135A1 (en) * 2021-07-19 2023-01-26 Context Biopharma Inc. Processes of making onapristone and intermediates thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2528434B1 (fr) 1982-06-11 1985-07-19 Roussel Uclaf Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament
FR2522328B1 (fr) 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
BE1004905A4 (fr) * 1987-12-30 1993-02-23 Roussel Uclaf Nouveaux derives 17beta-oh 19-nor steroides substitues en 17alpha, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
JPH02188599A (ja) * 1988-11-16 1990-07-24 Roussel Uclaf 3―ケト―デルタ―4,9―19―ノルステロイドから誘導される新物質及びそれらよりなる薬剤
DE3921059A1 (de) 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
FR2651435A1 (fr) 1989-09-07 1991-03-08 Roussel Uclaf Nouvelle utilisation de composes anti-progestomimetiques.
DE4018167A1 (de) 1990-06-01 1991-12-05 Schering Ag Verfahren zur herstellung von 10(beta)-h-steroiden
DE4042007A1 (de) 1990-12-22 1992-06-25 Schering Ag 6,7-modifizierte-11(beta)-aryl-4-estrene
DK0712311T3 (da) 1993-08-04 1999-06-21 Akzo Nobel Nv Antiglucocorticoidsteroider til behandling af angstlidelser
AU1439595A (en) 1993-12-22 1995-07-10 Salk Institute For Biological Studies, The Methods for reducing multidrug resistance
JPH10512889A (ja) 1995-02-02 1998-12-08 シェーリング アクチェンゲゼルシャフト 機能不全性子宮出血を治療する医薬を製造するためのプロゲステロンアンタゴニスト
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
IL122740A (en) 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
CN1085078C (zh) 1998-01-07 2002-05-22 沈志华 用于大月份引产的复合药物
US6512130B1 (en) 2000-09-05 2003-01-28 Council Of Scientific And Industrial Research Mifepristone analogue, process for the preparation thereof and use thereof
EP1285927A3 (de) * 2001-08-16 2005-06-29 Schering Aktiengesellschaft Verwendung von Glucocorticoid-Rezeptorantagonisten zur Vorbeugung und Behandlung von Erkrankungen des männlichen Reproduktionssystems
US7250408B2 (en) 2002-12-16 2007-07-31 Bayer Schering Pharma Ag Glucocorticoid receptor antagonists for prophylaxis and therapy of glucocorticoid-mediated hypogonadism, of sexual dysfunction and/or infertility
ATE453660T1 (de) * 2006-02-17 2010-01-15 Janssen Pharmaceutica Nv 17-phosphor-steroid-derivate als progesteron- rezeptormodulatoren
EP3020706A1 (en) 2006-03-29 2016-05-18 The Regents Of The University Of California Diarylthiohydantoin compounds useful for the treatment of a hyperproliferative disorder
HRP20160689T1 (hr) 2007-04-20 2016-07-15 Preglem S.A. Selektivni modulatori progesterona za tretman uterinog krvarenja
JP5804395B2 (ja) 2011-02-03 2015-11-04 ポップ テスト オンコロジー エルエルシー 診断と治療のためのシステムおよび方法
EP2545922A1 (en) 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids
US20130029953A1 (en) * 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
EP2817019A4 (en) 2012-02-24 2016-04-06 Univ Chicago METHOD AND COMPOSITIONS RELATED TO GLUCOCORTICOIDREZEPTORANTAGONISM AND PROSTATE CANCER
EP2641602A1 (en) 2012-03-23 2013-09-25 PregLem S.A. Method for treating gynecological diseases
US9096641B2 (en) * 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
EP3079475B1 (en) 2013-12-11 2020-10-07 Sloan-kettering Institute For Cancer Research Glucocorticoid inhibitors for treatment of prostate cancer
CN104530166B (zh) 2014-12-04 2016-08-24 陕西汉江药业集团股份有限公司 选择性还原4,6-共轭双烯-3-酮甾体化合物的方法
CN108713023B (zh) 2015-12-23 2021-10-26 欧瑞克制药公司 糖皮质激素受体抑制剂
CA3009522A1 (en) * 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
US11110103B2 (en) 2015-12-23 2021-09-07 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
EP3523315B1 (en) 2016-10-07 2021-03-24 Oric Pharmaceuticals, Inc. Inhibitor of glucocorticoid receptor
WO2018227129A1 (en) 2017-06-09 2018-12-13 Regents Of The University Of Minnesota Skin care formulations and skin cancer treatment
WO2019200156A1 (en) 2018-04-11 2019-10-17 Oric Pharmaceuticals, Inc. Solid forms and formulations comprising a glucocorticoid receptor antagonist and uses thereof

Similar Documents

Publication Publication Date Title
JP2019500374A5 (cg-RX-API-DMAC10.html)
JP2019034943A5 (cg-RX-API-DMAC10.html)
JP2016506369A5 (cg-RX-API-DMAC10.html)
JP2015520140A5 (cg-RX-API-DMAC10.html)
JP2016506958A5 (cg-RX-API-DMAC10.html)
JP2018522879A5 (cg-RX-API-DMAC10.html)
JP2016520131A5 (cg-RX-API-DMAC10.html)
JP2019524883A5 (cg-RX-API-DMAC10.html)
JP2017502940A5 (cg-RX-API-DMAC10.html)
JP2015514806A5 (cg-RX-API-DMAC10.html)
JP2019500376A5 (cg-RX-API-DMAC10.html)
JP2016537366A5 (cg-RX-API-DMAC10.html)
JP2016525130A5 (cg-RX-API-DMAC10.html)
JP2018510139A5 (cg-RX-API-DMAC10.html)
JP2017537937A5 (cg-RX-API-DMAC10.html)
JP2016526558A5 (cg-RX-API-DMAC10.html)
JP2016512520A5 (cg-RX-API-DMAC10.html)
JP2013537203A5 (cg-RX-API-DMAC10.html)
JP2017501237A5 (cg-RX-API-DMAC10.html)
JP2016531868A5 (cg-RX-API-DMAC10.html)
JP2017538773A5 (cg-RX-API-DMAC10.html)
JP2016503799A5 (cg-RX-API-DMAC10.html)
JP2018529650A5 (cg-RX-API-DMAC10.html)
JP2019531279A5 (cg-RX-API-DMAC10.html)
JP2015518899A5 (cg-RX-API-DMAC10.html)